Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: A meta-analysis

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 6, 2010, Pages 675-683

  Lee, Meng ^a,c   Saver, Jeffrey L ^a   Huang, Wen Hung ^e   Chow, Jessica ^b   Chang, Kuo Hsuan ^d   Ovbiagele, Bruce ^a  

^a Stroke Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular diseases; Coronary artery disease; Cystatin C; Meta analyses; Risk factors; Stroke

Indexed keywords

CYSTATIN C;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW;

AGED; BIOLOGICAL MARKERS; CORONARY DISEASE; CYSTATIN C; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RISK; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 78650191250     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.957696     Document Type: Article

References (45)

1. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
3. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-2081.
4. Rule AD, Larson TS, Bergstralh EJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929-937.
5. Pucci L, Triscornia S, Lucchesi D, Penno G. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480-488.
6. Coll E, Botey A, Alvarez L, Poch E, Darnell A. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-34.
7. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79-83.
8. Shlipak MG, Sarnak MJ, Katz R, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
9. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115:173-179.
10. Stroup DF, Berlin JA, Morton SC, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
11. Levey AS, Coresh J, Balk E, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
12. Harris RP, Helfand M, Woolf SH, Atkins D. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35.
13. Loosemore M, Knowles CH, Whyte GP. Amateur boxing and risk of chronic traumatic brain injury: systematic review of observational studies. BMJ. 2007;335:809.
14. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-1996.
15. Seronie-Vivien S, Delanaye P, Cristol JP. Cystatin C: current position and future prospects. Clin Chem Lab Med. 2008;46:1664-1686.
16. Finney H, Newman DJ, Gruber W, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43:1016-1022.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
19. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Oxford, UK: The Cochrane Collaboration; 2008.
20. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-1055.
21. Poole C, Greenland S. Random-effects meta-analyses are not always conservative. Am J Epidemiol. 1999;150:469-475.
22. Menon V, Shlipak MG, Wang X, Sarnak MJ. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med. 2007;147:19-27.
23. Loew M, Hoffmann MM, Koenig W, Rothenbacher D. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arterioscler Thromb Vasc Biol. 2005;25:1470-1474.
24. Luc G, Bard JM, Lesueur C, Fruchart JC, Ducimetiere P. Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis. 2006;185:375-380.
25. Ichimoto E, Jo K, Kobayashi Y, Komuro I. Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction. Circ J. 2009;73:1669-1673.
26. Jernberg T, Lindahl B, James S, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342-2348.
27. Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11:354-360.
28. Sarnak MJ, Katz R, Stehman-Breen CO, Shlipak MG. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005;142:497-505.
29. Shlipak MG, Katz R, Sarnak MJ, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237-246.
30. Shlipak MG, Wassel Fyr CL, Fried LF. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006;17:254-261.
31. Deo R, Fyr CL, Fried LF, Shlipak MG. Kidney dysfunction and fatal cardiovascular disease: an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J. 2008;155:62-68.
32. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med. 2008;121:50-57.
33. Keller T, Messow CM, Lubos E, Schnabel RB. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J. 2009;30:314-320.
34. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321-327. (Pubitemid 40175801)
35. Melander O, Newton-Cheh C, Almgren P, Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302:49-57.
36. Naruse H, Ishii J, Kawai T, Ozaki Y. Cystatin C in acute heart failure without advanced renal impairment. Am J Med. 2009;122:566-573.
37. Ni L, Lu J, Hou LB, Yan JT, Wang DW. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke. 2007;38:3287-3288.
38. Zethelius B, Berglund L, Sundstrom J, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116.
39. Windhausen F, Hirsch A, Fischer J, de Winter RJ. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem. 2009;55:1118-1125.
40. Arimoto T, Takeishi Y, Niizeki T, Kubota I. Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail. 2005;11:595-601.
41. Hoke M, Amighi J, Mlekusch W, Schillinger M. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke. 2010;41:674-679.
42. Taglieri N, Fernandez-Berges DJ, Kaski JC. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis. 2010;209:300-305.
43. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009;55:1932-1943.
44. Levey AS, Eckardt KU, Tsukamoto Y, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.
45. Hohn AR, Dwyer KM, Dwyer JH. Blood pressure in youth from four ethnic groups: the Pasadena Prevention Project. J Pediatr. 1994;125:368-373.